Immunologic indicators associated with better prognosis included tumor-infiltrating macrophages (TIMs) and lymphocytes (TILs) [40–42], effective CD4+ T cells including Th17 cells [43], a high effector T cell (Teff) to regulatory T cell (Treg) ratio [43], a high neutrophil to lymphocyte ratio (NLR) and a high platelet to lymphocyte ratio (PLR) [44]. This evidence concerns the gene CD4 and neoplasm.